Home > Oncology > ESMO 2021 > Melanoma > Updated results of SECOMBIT trial

Updated results of SECOMBIT trial

Presented By
Prof. Paolo Ascierto, Istituto Nazionale Tumori "Fondazione Pascale", Italy
ESMO 2021
First OS data of the SECOMBIT trial did not (yet) show the optimum sequential approach with immunotherapy and targeted therapy in patients with BRAF-mutated metastatic melanoma. Treatment with targeted therapy (BRAF and MEK inhibitors) and immune-checkpoint inhibitors (anti-CTLA4, anti-PD-1) have improved the outcome of BRAF-mutated metastatic melanoma patients in first line, but the best sequencing remains an open question. In the SECOMBIT trial (NCT02631447) immunotherapy and targeted therapy were given sequentially [1]. This phase 2 study included 251 patients with untreated, metastatic BRAF-mutated melanoma, who were randomised 1:1:1 to 3 arms: encorafenib plus binimetinib until progression, followed by ipilimumab plus nivolumab (arm A); ipilimumab plus nivolumab until progression, followed by encorafenib plus binimetinib (arm B); or ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on